公开(公告)号：US3895114A

公开(公告)日：1975-07-15

申请号：US33360073

申请日：1973-02-20

Applicant: ABBOTT LAB

Inventor： JONES PETER HADLEY ,  MARTIN YVONNE CONNOLLY

IPC: A61K31/445 ,  A61K27/00

CPC classification number: A61K31/445

Abstract: Method of treating hypertension by administering to a hypertensive patient a therapeutically effective amount of a compound of the Formula

WHEREIN R1, R2, and R3 each are hydrogen, alkyl, cycloalkyl or aryl.

Abstract translation: 通过向高血压患者施用治疗有效量的式WHEREIN R1，R2和R3的化合物各自为氢，烷基，环烷基或芳基的治疗高血压的方法。

公开(公告)号：US3901926A

公开(公告)日：1975-08-26

申请号：US44203474

申请日：1974-02-13

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  LYNN KATHLEEN RILEY ,  MARTIN YVONNE CONNOLLY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94 ,  C07D307/83

CPC classification number: C07D213/30 ,  C07C37/055 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94 ,  C07C39/367

Abstract: Alkylphenyl benzopyrans represented by the formula

WHEREIN N IS 1 OR 2; EACH R and R1 are the same or different members of the group consisting of hydrogen or loweralkyl; R2 is loweralkyl; R3 is hydrogen; Y is a straight or branched chain alkylene group having from one to ten carbon atoms; and each R4 and R5 and R6 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl and Z is C or N and the pharmaceutically acceptable salts thereof.

公开(公告)号：US3903147A

公开(公告)日：1975-09-02

申请号：US40890273

申请日：1973-10-23

Applicant: ABBOTT LAB

Inventor： KYNCL JAROSLAV ,  RILEY KATHLEEN ,  MARTIN YVONNE CONNOLLY ,  OURS CARROLL WAYNE

IPC: C07C237/00 ,  C07C103/50

CPC classification number: C07C237/00

Abstract: Covers a gamma -glutamyl amide of dopamine selected from the group consisting of

and a pharmaceutically acceptable acid addition salt thereof. Also covers the use of said gamma -glutamyl amide to increase renal blood flow by administering said amide to warm-blooded mammals.

Abstract translation: 覆盖选自HO | HO-CH 2 -CH 2 -NH 2 | PARALLEL C-CH 2 -CH 2 -CH-C-OH平行| ONH 2的多巴胺的γ-谷氨酰胺及其药学上可接受的酸加成盐。 还涵盖了通过将所述酰胺施用于温血哺乳动物来增加所述γ-谷氨酰胺以增加肾血流量的用途。

公开(公告)号：FI60004B

公开(公告)日：1981-07-31

申请号：FI92174

申请日：1974-03-26

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  LYNN KATHLEEN RILEY ,  MARTIN YVONNE CONNOLLY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94

Abstract: 1459564 Derivatives of dibenzopyran and cyclopentabenzopyran ABBOTT LABORATORIES 1 April 1974 [2 April 1973 13 Feb 1974] 14404/74 Heading C2C The invention comprises compounds of formulµ and the pharmaceutically acceptable salts of (I), (II) and (III), wherein n is 1 or 2; R and R 1 are each H or C 1-6 alkyl [but in the pyrone compound (XIII), H or Me]; R 2 is C 1-6 alkyl; Y is C 1-10 alkylene; R 4 , R 5 , R 6 are each H, halogen, CF 3 or C 1-6 alkyl; and Z is C or N. In examples, (XIII) are prepared by reacting an ethyl cyclopentanone (or cyclohexanone)-2-carboxylate with an appropriate 5-aralkylresorcinol (A), and converted into (I) and (II) by reaction with R 2 MgBr, followed optionally by hydrogenation to give (III). Starting materials prepared are the dimethyl ethers of (A), the benzene compounds where Q is CH : CHCO 2 H, CH 2 CH 2 CO 2 H, (CH 2 ) 3 OH, (CH 2 ) 3 Br, (CH 2 ) 5 OH and (CH 2 ) 3 Br, and the compounds 3,5-(MeO) 2 C 6 H 3 CR 0 R 0 - alkylene-Ar where CR 0 R 0 is CO or one R‹ is Me and the other is OH, and Ar is R 4 R 5 R 6 C 5 HZ-. Therapeutic compositions for oral, parenteral or rectal administration comprise the above compounds (Ia), which are analgesics, mild tranquillizers and antidiarrhoeals.

公开(公告)号：DE2415697A1

公开(公告)日：1974-10-17

申请号：DE2415697

申请日：1974-04-01

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  LYNN KATHLEEN RILEY ,  MARTIN YVONNE CONNOLLY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94 ,  C07D7/20 ,  A61K27/00

Abstract: 1459564 Derivatives of dibenzopyran and cyclopentabenzopyran ABBOTT LABORATORIES 1 April 1974 [2 April 1973 13 Feb 1974] 14404/74 Heading C2C The invention comprises compounds of formulµ and the pharmaceutically acceptable salts of (I), (II) and (III), wherein n is 1 or 2; R and R 1 are each H or C 1-6 alkyl [but in the pyrone compound (XIII), H or Me]; R 2 is C 1-6 alkyl; Y is C 1-10 alkylene; R 4 , R 5 , R 6 are each H, halogen, CF 3 or C 1-6 alkyl; and Z is C or N. In examples, (XIII) are prepared by reacting an ethyl cyclopentanone (or cyclohexanone)-2-carboxylate with an appropriate 5-aralkylresorcinol (A), and converted into (I) and (II) by reaction with R 2 MgBr, followed optionally by hydrogenation to give (III). Starting materials prepared are the dimethyl ethers of (A), the benzene compounds where Q is CH : CHCO 2 H, CH 2 CH 2 CO 2 H, (CH 2 ) 3 OH, (CH 2 ) 3 Br, (CH 2 ) 5 OH and (CH 2 ) 3 Br, and the compounds 3,5-(MeO) 2 C 6 H 3 CR 0 R 0 - alkylene-Ar where CR 0 R 0 is CO or one R‹ is Me and the other is OH, and Ar is R 4 R 5 R 6 C 5 HZ-. Therapeutic compositions for oral, parenteral or rectal administration comprise the above compounds (Ia), which are analgesics, mild tranquillizers and antidiarrhoeals.

公开(公告)号：CH595375A5

公开(公告)日：1978-02-15

申请号：CH461774

申请日：1974-04-02

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  LYNN KATHLEEN RILEY ,  MARTIN YVONNE CONNOLLY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94 ,  C07D311/78 ,  C07D405/10

Abstract: 1459564 Derivatives of dibenzopyran and cyclopentabenzopyran ABBOTT LABORATORIES 1 April 1974 [2 April 1973 13 Feb 1974] 14404/74 Heading C2C The invention comprises compounds of formulµ and the pharmaceutically acceptable salts of (I), (II) and (III), wherein n is 1 or 2; R and R 1 are each H or C 1-6 alkyl [but in the pyrone compound (XIII), H or Me]; R 2 is C 1-6 alkyl; Y is C 1-10 alkylene; R 4 , R 5 , R 6 are each H, halogen, CF 3 or C 1-6 alkyl; and Z is C or N. In examples, (XIII) are prepared by reacting an ethyl cyclopentanone (or cyclohexanone)-2-carboxylate with an appropriate 5-aralkylresorcinol (A), and converted into (I) and (II) by reaction with R 2 MgBr, followed optionally by hydrogenation to give (III). Starting materials prepared are the dimethyl ethers of (A), the benzene compounds where Q is CH : CHCO 2 H, CH 2 CH 2 CO 2 H, (CH 2 ) 3 OH, (CH 2 ) 3 Br, (CH 2 ) 5 OH and (CH 2 ) 3 Br, and the compounds 3,5-(MeO) 2 C 6 H 3 CR 0 R 0 - alkylene-Ar where CR 0 R 0 is CO or one R‹ is Me and the other is OH, and Ar is R 4 R 5 R 6 C 5 HZ-. Therapeutic compositions for oral, parenteral or rectal administration comprise the above compounds (Ia), which are analgesics, mild tranquillizers and antidiarrhoeals.

公开(公告)号：NO741140L

公开(公告)日：1974-10-03

申请号：NO741140

申请日：1974-03-29

Applicant: ABBOTT LAB

Inventor： LYNN KATHLEEN RILEY ,  WINN MARTIN ,  MARTIN YVONNE CONNOLLY

IPC: C07D311/80 ,  C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/94

公开(公告)号：FI60004C

公开(公告)日：1981-11-10

申请号：FI92174

申请日：1974-03-26

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  LYNN KATHLEEN RILEY ,  MARTIN YVONNE CONNOLLY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94

Abstract: 1459564 Derivatives of dibenzopyran and cyclopentabenzopyran ABBOTT LABORATORIES 1 April 1974 [2 April 1973 13 Feb 1974] 14404/74 Heading C2C The invention comprises compounds of formulµ and the pharmaceutically acceptable salts of (I), (II) and (III), wherein n is 1 or 2; R and R 1 are each H or C 1-6 alkyl [but in the pyrone compound (XIII), H or Me]; R 2 is C 1-6 alkyl; Y is C 1-10 alkylene; R 4 , R 5 , R 6 are each H, halogen, CF 3 or C 1-6 alkyl; and Z is C or N. In examples, (XIII) are prepared by reacting an ethyl cyclopentanone (or cyclohexanone)-2-carboxylate with an appropriate 5-aralkylresorcinol (A), and converted into (I) and (II) by reaction with R 2 MgBr, followed optionally by hydrogenation to give (III). Starting materials prepared are the dimethyl ethers of (A), the benzene compounds where Q is CH : CHCO 2 H, CH 2 CH 2 CO 2 H, (CH 2 ) 3 OH, (CH 2 ) 3 Br, (CH 2 ) 5 OH and (CH 2 ) 3 Br, and the compounds 3,5-(MeO) 2 C 6 H 3 CR 0 R 0 - alkylene-Ar where CR 0 R 0 is CO or one R‹ is Me and the other is OH, and Ar is R 4 R 5 R 6 C 5 HZ-. Therapeutic compositions for oral, parenteral or rectal administration comprise the above compounds (Ia), which are analgesics, mild tranquillizers and antidiarrhoeals.

公开(公告)号：NO143943C

公开(公告)日：1981-05-13

申请号：NO741140

申请日：1974-03-29

Applicant: ABBOTT LAB

Inventor： WINN MARTIN ,  LYNN KATHLEEN RILEY ,  MARTIN YVONNE CONNOLLY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94

Abstract: 1459564 Derivatives of dibenzopyran and cyclopentabenzopyran ABBOTT LABORATORIES 1 April 1974 [2 April 1973 13 Feb 1974] 14404/74 Heading C2C The invention comprises compounds of formulµ and the pharmaceutically acceptable salts of (I), (II) and (III), wherein n is 1 or 2; R and R 1 are each H or C 1-6 alkyl [but in the pyrone compound (XIII), H or Me]; R 2 is C 1-6 alkyl; Y is C 1-10 alkylene; R 4 , R 5 , R 6 are each H, halogen, CF 3 or C 1-6 alkyl; and Z is C or N. In examples, (XIII) are prepared by reacting an ethyl cyclopentanone (or cyclohexanone)-2-carboxylate with an appropriate 5-aralkylresorcinol (A), and converted into (I) and (II) by reaction with R 2 MgBr, followed optionally by hydrogenation to give (III). Starting materials prepared are the dimethyl ethers of (A), the benzene compounds where Q is CH : CHCO 2 H, CH 2 CH 2 CO 2 H, (CH 2 ) 3 OH, (CH 2 ) 3 Br, (CH 2 ) 5 OH and (CH 2 ) 3 Br, and the compounds 3,5-(MeO) 2 C 6 H 3 CR 0 R 0 - alkylene-Ar where CR 0 R 0 is CO or one R‹ is Me and the other is OH, and Ar is R 4 R 5 R 6 C 5 HZ-. Therapeutic compositions for oral, parenteral or rectal administration comprise the above compounds (Ia), which are analgesics, mild tranquillizers and antidiarrhoeals.

公开(公告)号：AU6664074A

公开(公告)日：1975-09-18

申请号：AU6664074

申请日：1974-03-14

Applicant: ABBOTT LAB

Inventor： MARTIN YVONNE CONNOLLY ,  WINN MARTIN ,  LYNN KATHLEEN RILEY

IPC: C07C37/055 ,  C07D213/30 ,  C07D213/50 ,  C07D311/80 ,  C07D311/94 ,  A61K27/00 ,  C07D7/24 ,  C07D99/04

Abstract: 1459564 Derivatives of dibenzopyran and cyclopentabenzopyran ABBOTT LABORATORIES 1 April 1974 [2 April 1973 13 Feb 1974] 14404/74 Heading C2C The invention comprises compounds of formulµ and the pharmaceutically acceptable salts of (I), (II) and (III), wherein n is 1 or 2; R and R 1 are each H or C 1-6 alkyl [but in the pyrone compound (XIII), H or Me]; R 2 is C 1-6 alkyl; Y is C 1-10 alkylene; R 4 , R 5 , R 6 are each H, halogen, CF 3 or C 1-6 alkyl; and Z is C or N. In examples, (XIII) are prepared by reacting an ethyl cyclopentanone (or cyclohexanone)-2-carboxylate with an appropriate 5-aralkylresorcinol (A), and converted into (I) and (II) by reaction with R 2 MgBr, followed optionally by hydrogenation to give (III). Starting materials prepared are the dimethyl ethers of (A), the benzene compounds where Q is CH : CHCO 2 H, CH 2 CH 2 CO 2 H, (CH 2 ) 3 OH, (CH 2 ) 3 Br, (CH 2 ) 5 OH and (CH 2 ) 3 Br, and the compounds 3,5-(MeO) 2 C 6 H 3 CR 0 R 0 - alkylene-Ar where CR 0 R 0 is CO or one R‹ is Me and the other is OH, and Ar is R 4 R 5 R 6 C 5 HZ-. Therapeutic compositions for oral, parenteral or rectal administration comprise the above compounds (Ia), which are analgesics, mild tranquillizers and antidiarrhoeals.